INDV 株価分析 — Indivior PLC Ordinary Shares (Healthcare >> Drug Manufacturers - Specialty & Generic)
INDV に関するよくある質問
INDVのPER(株価収益率)は?
Indivior PLC Ordinary Shares(INDV)は現在PER 18.94倍で取引されています。
INDVのROE(自己資本利益率)は?
Indivior PLC Ordinary SharesのROEは-174.31%です。
INDVの配当利回りは?
Indivior PLC Ordinary Sharesの配当利回りは0.00%です。
INDVの品質スコア(Quality Score)は?
当社のAIはINDVの総合財務品質を100点中69点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
INDVは今が買い時ですか?
当社AIのタイミングスコアは100点中89点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
INDVはどのセクターに属しますか?
Indivior PLC Ordinary SharesはHealthcare >> Drug Manufacturers - Specialty & Genericセクターに分類されます(NASDAQ市場)
INDV AI Analysis Summary
Our AI summary for INDV: Indivior PLC Ordinary Shares (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 18.94, ROE of -174.31%, a dividend yield of 0.00%. Its financial Quality Score stands at 69/100 — mid-range fundamentals relative to the market. The AI Timing Score is 89/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 40.01
Price
-0.21
(-0.52%)
Day Change
|
|
|---|
INDV, ファンダメンタルスコアはok ( ファンダメンタル = 69) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- NEUTRAL
- Signal Description
- Company financial health is OK
- Reason
-
ROEが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
57% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 97 |
| Magic Formula Rank by ROA |
575
|
| Magic Formula Rank by ROE |
575
|
| Magic Formula Rank by ROIC |
582
|
| Price | 40.01 |
| PBV / Sector |
-33.02 / 3.22
|
| Earning Per Share | 2.11 |
| PE / Sector |
18.94 / 29.79
|
| PEG or PE/Growth / Sector |
0.01 / 0.13
GREAT
|
| Average 1M Daily Value |
55.62 M
|
| Average 1W Daily Value |
49.45 M
GREAT
|
| Timing Factors |
|
28% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
66% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:01 |
| Symbol | INDV |
| Name | INDIVIOR PLC ORDINARY SHARES |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 118.20 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 4,754.19 / 10,754.62 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 10710 Midlothian Turnpike, North Chesterfield, VA, United States, 23235
Phone: 804 379 1040
Website: https://www.indivior.com
Employees: 827
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: Indivior Pharmaceuticals, Inc., together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. It develops medicines to treat substance use disorders. The company's core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; and SUBOXONE Film, a buprenorphine and naloxone sublingual film. It also manufactures SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX Tablet, a buprenorphine sublingual tablet for the treatment of opioid use disorder (OUD). In addition, the company is developing INDV-2000, a selective orexin-1 receptor antagonist that is in Phase 2 clinical trial for the treatment of moderate to severe OUD; and INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc. The company was formerly known as Indivior PLC. and changed its name to Indivior Pharmaceuticals, Inc. in January 2026. Indivior Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
Google